Skip to main content

Table 3 Detection rates and capabilities of cfDNA screening (n = 188)

From: Obstetrical provider knowledge and attitudes towards cell–free DNA screening: results of a cross-sectional national survey

Question:

OB/GYN (n = 114)

% [95% CI]

MFM (n = 29)

% [95% CI]

GP (n = 31)

% [95%CI]

MW (n = 14)

% [95% CI]

p-value

Correctly identified that detection rates are NOT equal for different trisomies such as 13, 18, and 21 using cfDNA.

53.5% [44.2–62.5]

82.8% [64.1–92.8]

41.9% [25.8–60.0]

14.3% [3.4–44.3]

p = 0.000

Correctly identified that cfDNA has a better detection rate for Trisomy 21 than currently available prenatal screening methods such as the First Trimester Combined Test or Integrated Prenatal Screening.

88.5% [81.1–93.2]

100.0%

67.7% [49.3–81.9]

50.0% [25.1–74.9]

p = 0.000

Correctly identified that NOT all the chromosomal abnormalities diagnosed via amniocentesis can also be readily detected via cfDNA.

85.0% [77.0–90.5]

96.6% [78.4–99.5]

61.3% [43.0–76.8]

71.4% [42.7–89.4]

p = 0.017

  1. *Abbreviations: OB/GYN Obstetrician/Gynecologist, MFM Maternal Fetal Medicine Specialist, GP General Practitioner, MW Midwife